Breast Cancer Campaign, comments on research presented today about T-DM1, a new ‘smart’ drug for breast cancer
Dr Lisa Wilde, Director of Research at Breast Cancer Campaign, comments on research presented today about T-DM1, a new ‘smart’ drug, which is the first of its kind to harness a targeted drug – Herceptin - to deliver chemotherapy directly to breast cancer cells.“This study is a positive development for women with advanced HER2-postive breast cancer, who currently have limited treatment options available to them."As well as keeping advanced HER2-postive breast cancer at bay for longer, T-DM1 offers other considerable benefits to this particular group. Patients appear to experience fewer
